Form 4: Biostem Technologies Executive Reports Stock Transaction
Insider Transaction (Form 4)
Barry Hassett, Chief Commercial Officer of Biostem Technologies, reported multiple transactions in common stock on November 1, 2026.
Summary
- Option exercise/conversion: acquired 253 Common Stock on November 1, 2026; holds 5,256 after (Direct).
- Option exercise/conversion: disposed of 253 Restricted Stock Units on November 1, 2026; holds 1,266 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Barry Hassett — Officer (Chief Commercial Officer)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-11-01 | Option exercise/conversion | Common Stock | 253 | — | — | 5,256 |
| 2026-11-01 | Option exercise/conversion | Restricted Stock Units | 253 | — | — | 1,266 |
Key Dates
| Date | Description |
|---|---|
| 2026-11-01 | Option exercise/conversion (253 shares) |
| 2026-11-01 | Option exercise/conversion (253 shares) |
Keywords
insider transaction, Form 4, BSEM, BioStem Technologies, Inc., neutral, Barry Hassett
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.